Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
1-Minute Consult

Is exercise restriction necessary in patients with pericarditis?

Felix Berglund, MD and Allan L. Klein, MD
Cleveland Clinic Journal of Medicine August 2022, 89 (8) 437-441; DOI: https://doi.org/10.3949/ccjm.89a.21120
Felix Berglund
Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allan L. Klein
Center for Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Find this author on Cleveland Clinic
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

A 47-year-old woman presents with recurrent episodes of pleuritic chest pain. She is physically active and exercises 5 times per week on average, although recently she has had to stop after noticing worsening of her symptoms with strenuous exercise. Inflammatory markers are found to be elevated, and echocardiography reveals a new small pericardial effusion. Cardiac magnetic resonance imaging (MRI) with gadolinium contrast reveals circumferential delayed hyperenhancement of the pericardium (Figure 1). A diagnosis of acute pericarditis is made, and the patient is started on anti-inflammatory therapy. When is it safe to recommend resumption of her physical activity?

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Cardiac magnetic resonance imaging with gadolinium contrast showing delayed contrast enhancement of the pericardium on fat-suppression imaging sequences in a 47-year-old female with acute pericarditis. The arrows point to the circumferential contrast enhancement of the pericardium. Our experience suggests that complete remission may take as long as 3 to 5 years.

Although there is little published evidence, experts recommend against participation in exercise and competitive sports during episodes of acute and recurrent pericarditis and 1 to 3 months after an acute episode to ensure resolution of disease.

EXERCISE AND PERICARDITIS: TRIGGERS AND MECHANISMS

Physical exercise is thought to worsen pericardial inflammation, and it has been implicated as a trigger for inflammation in genetically predisposed patients.1,2 The proposed mechanisms include a tachycardia-mediated increase in shear stress through friction of the pericardial layers and an increase in the release of free radicals causing oxidative stress through enhanced blood supply to the pericardium.1 Additionally, extreme physical exercise in elite athletes can decrease the innate and adaptive immune response.3 However, this interplay and its relevance to the clinical course of pericarditis in elite athletes has not been studied specifically. Exercise restriction is commonly recommended to patients with pericarditis as a means to decrease symptoms and the risk of complications, even though published evidence of a causative relationship between exercise and worsening pericarditis is limited to case reports.4

Elevations in heart rate appear to be particularly implicated in worsening pericardial inflammation, and studies have shown a correlation between C-reactive protein levels and heart rate in patients hospitalized with acute pericarditis.5 Local inflammation from pericarditis has been proposed as a mechanism that worsens tachycardia, which in turn can perpetuate a vicious cycle of inflammation.6 Some experts have suggested maintaining heart rates below 100 beats per minute in patients with pericarditis, and a role has been proposed for using cardiac MRI to monitor disease activity in order to guide the resumption of exercise.4

In an observational study by Imazio et al,7 beta-blockers were administered to patients with acute pericarditis targeting a heart rate of less than 70 beats per minute. Patients who received beta-blockers had a lower rate of symptom recurrence at 3 weeks (4% vs 14%, P = .024) and a trend toward fewer recurrences at 18 months.7 Although mechanisms other than heart rate reduction, such as downregulation of proinflammatory cytokines, could contribute to symptom reduction in these patients, this study indirectly supports the contention of exercise restriction to lower heart rates in patients with acute pericarditis. Of note, no randomized clinical trials using heart-rate-lowering therapies in this patient population have been conducted.

SOCIETY GUIDELINES

Several professional societies have published recommendations on physical exercise in patients with pericarditis (Table 1),8–10 but the recommendations are generally not supported by data from randomized clinical trials and instead rely on observational data and expert opinion. Moreover, the guidelines emphasize recommendations for return to competitive sports for athletes rather than recommendations on activity levels in the general population of nonathletes.

View this table:
  • View inline
  • View popup
TABLE 1

Exercise recommendations in patients with isolated pericarditisa

The European Association of Preventive Cardiology (EAPC) released recommendations on return to play for athletes in 2019.8 They recommend against participation in competitive sports during the acute phase of pericarditis and not resuming sports activity for 1 to 3 months after resolution of the active phase. Return to play was deemed reasonable if biomarkers had normalized, left ventricular function was normal, and no resting or exercise-induced ventricular arrhythmias could be detected on 24-hour electrocardiography monitoring or exercise electrocardiography.

The European Society of Cardiology (ESC) released guidelines on sports cardiology and exercise in patients with cardiovascular disease in 2020.9 They provide more generalized recommendations for the general population of patients in terms of leisurely activity. In contrast to the EAPC recommendations, both competitive sports and leisure-time exercise are actively discouraged until complete recovery from pericarditis. Similar to the EAPC recommendations, return to activity is recommended after a period of 30 days to 3 months after resolution of disease, depending on severity.

The American Heart Association and American College of Cardiology (AHA/ACC) released a joint scientific statement in 2015 on disqualification and eligibility for competitive athletes with cardiovascular abnormalities.10 In concordance with the ESC and EAPC recommendations, the AHA/ACC statement recommends against participation in competitive sports during the acute phase of pericarditis. Return to full activity is recommended in the complete absence of evidence for the disease. They provide no specific guidance in terms of timing of return or stratification of physical activity for athletes and nonathletes.

MYOPERICARDITIS

Myopericarditis is a term used to describe predominant pericarditis with concurrent myocardial involvement as defined by the detection of biomarkers of myocardial necrosis in the blood. The relative myocardial involvement can be variable and ranges from isolated inflammation of the pericardium to perimyocarditis, a term used to describe predominant myocardial involvement typically evidenced by new focal or diffuse left ventricular systolic dysfunction. Figure 2 shows a proposed algorithm for determining exercise restriction in patients with these conditions, based on ESC and AHA/ACC recommendations.9,10

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

Proposed algorithm for exercise restriction in pericarditis with or without myocardial involvement, based on European Society of Cardiology and American Heart Association/American College of Cardiology recommendations. The detection of biomarkers of myocardial injury indicates active myocardial inflammation, which necessitates exercise restriction for 3 to 6 months regardless of left ventricular function.

Any evidence of myocardial involvement is considered a contraindication to exercise regardless of left ventricular systolic function, and professional societies recommend exercise electrocardiography, 24-hour Holter monitoring, and echocardiography no less than 3 to 6 months before resuming exercise.11 The underlying rationale behind this recommendation is the concern that exercise can worsen the inflammatory response with potentially fatal consequences. Indeed, sudden cardiac death without prodromal symptoms has been reported in patients with myocarditis following strenuous activity, and mouse models of myocarditis have shown an association between daily exercise and sudden cardiac death.9,11 Return to exercise can be guided by the use of cardiac MRI to assess for delayed hyperenhancement and myocardial edema on T2-weighted imaging, enabling clinicians to tailor their recommendations for asymptomatic patients who may or may not have active inflammation on imaging. And while there is no clear consensus about the appropriate use of MRI, the ESC guidelines recommend repeating it if edema or delayed hyperenhancement was present on the initial MRI.9,11

Recently, myocarditis has gained increased relevance given its association with COVID-19 infection. However, the overall risk is low. A 2021 study found evidence of cardiac involvement in 0.7% of athletes and 3% in athletes who underwent primary screening MRI.12

THE BOTTOM LINE

Patients with isolated pericarditis should refrain from physical exercise during acute episodes. Athletes should avoid competitive sports for 1 to 3 months after an acute episode, depending on the severity, as part of shared decision-making with their treating clinicians. It is reasonable to resume physical activity if biomarkers (C-reactive protein, erythrocyte sedimentation rate) have normalized, left ventricular function is normal, and there are no residual abnormalities on electrocardiography.

Although specific guidance is lacking for the non-athlete population, we generally recommend patients to limit their physical activity to walking and to limit their active heart rate to 100 beats per minute as long as they are receiving anti-inflammatory medications for pericarditis.

Active myocardial involvement should be considered a contraindication to exercise, given its reported association with sudden cardiac death. There is insufficient evidence to routinely recommend beta-blockers to patients with acute pericarditis. However, it is reasonable therapy in patients in whom beta-blockers can have synergistic effects (eg, those with hypertension or atrial fibrillation) or if their resting heart rate was significantly elevated at baseline. We would aim to decrease the active heart rate to below 100 beats per minute.

BACK TO THE CASE SCENARIO

In the scenario presented earlier, our patient showed delayed hyperenhancement on cardiac MRI. In our experience, these imaging findings can resolve over the course of 3 to 5 years, and anecdotally, exercise can worsen both symptoms and radiologic evidence of disease activity. In light of this, for patients such as this, we would recommend continued exercise restriction if there is ongoing neovascularization or inflammation on MRI. However, acknowledging the health benefits of exercise during a risk-benefit discussion with the patient is always warranted.

Randomized trials are needed to validate the use of imaging to tailor exercise recommendations in acute pericarditis and to determine if there is a role for the use of emerging biologic treatments, such as the anti-interleukin 1 agents anakinra and rilonacept, in enabling a timely return to exercise and competitive sports.

DISCLOSURES

Dr. Klein reports advisor or review panel participation with Cardiol Therapeutics, Kiniksa, and Pfizer; consulting for Kiniksa Pharmaceuticals and Pfizer; and intellectual property rights with Elsevier and Wolters-Kluwer. Dr. Berglund reports no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

Acknowledgment

We acknowledge the contributions of Michael Emery, MD, whose insightful comments have increased the accuracy of this publication.

  • Copyright © 2022 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Grant JK,
    2. Shah NP
    . The impact of physical activity on pericarditis. Curr Cardiol Rep 2021; 23(10):150. doi:10.1007/s11886-021-01578-0
    OpenUrlCrossRef
  2. ↵
    1. Lachmann HJ,
    2. Papa R,
    3. Gerhold K, et al
    . The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis 2014; 73(12):2160–2167. doi:10.1136/annrheumdis-2013-204184
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Hurwitz B,
    2. Issa O
    . Management and treatment of myocarditis in athletes. Curr Treat Options Cardiovasc Med 2020; 22(12):65. doi:10.1007/s11936-020-00875-1
    OpenUrlCrossRef
  4. ↵
    1. Shah NP,
    2. Verma BR,
    3. Ala CK, et al
    . Exercise is good for the heart but not for the inflamed pericardium? JACC Cardiovasc Imaging 2019; 12(9):1880–1881. doi:10.1016/j.jcmg.2019.01.022
    OpenUrlFREE Full Text
  5. ↵
    1. Khoueiry Z,
    2. Roubille C,
    3. Nagot N, et al
    . Could heart rate play a role in pericardial inflammation? Med Hypotheses 2012; 79(4):512–515. doi:10.1016/j.mehy.2012.07.006
    OpenUrlCrossRefPubMed
  6. ↵
    1. Roubille F,
    2. Tournoux F,
    3. Roubille C, et al
    . Management of pericarditis and myocarditis: could heart-rate-reducing drugs hold a promise? Arch Cardiovasc Dis 2013; 106(12):672–679. doi:10.1016/j.acvd.2013.06.047
    OpenUrlCrossRef
  7. ↵
    1. Imazio M,
    2. Andreis A,
    3. Agosti A, et al
    . Usefulness of beta-blockers to control symptoms in patients with pericarditis. Am J Cardiol 2021; 146:115–119. doi:10.1016/j.amjcard.2021.01.032
    OpenUrlCrossRef
  8. ↵
    1. Pelliccia A,
    2. Solberg EE,
    3. Papadakis M, et al
    . Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2019; 40(1):19–33. doi:10.1093/eurheartj/ehy730
    OpenUrlCrossRefPubMed
  9. ↵
    1. Pelliccia A,
    2. Sharma S,
    3. Gati S, et al
    . 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021; 42(1):17–96. doi:10.1093/eurheartj/ehaa605
    OpenUrlCrossRef
  10. ↵
    1. Maron BJ,
    2. Udelson JE,
    3. Bonow RO, et al
    . Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. Circulation 2015; 132(22):e273–e280. doi:10.1161/CIR.0000000000000239
    OpenUrlFREE Full Text
  11. ↵
    1. Adler Y,
    2. Charron P,
    3. Imazio M, et al
    . 2015 ESC guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36(42):2921–2964. doi:10.1093/eurheartj/ehv318
    OpenUrlCrossRefPubMed
  12. ↵
    1. Moulson N,
    2. Petek BJ,
    3. Drezner JA, et al
    . SARS-CoV-2 cardiac involvement in young competitive athletes. Circulation 2021; 144(4): 256–266. doi:10.1161/CIRCULATIONAHA.121.054824
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 89 (8)
Cleveland Clinic Journal of Medicine
Vol. 89, Issue 8
1 Aug 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Is exercise restriction necessary in patients with pericarditis?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Is exercise restriction necessary in patients with pericarditis?
Felix Berglund, Allan L. Klein
Cleveland Clinic Journal of Medicine Aug 2022, 89 (8) 437-441; DOI: 10.3949/ccjm.89a.21120

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Is exercise restriction necessary in patients with pericarditis?
Felix Berglund, Allan L. Klein
Cleveland Clinic Journal of Medicine Aug 2022, 89 (8) 437-441; DOI: 10.3949/ccjm.89a.21120
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • EXERCISE AND PERICARDITIS: TRIGGERS AND MECHANISMS
    • SOCIETY GUIDELINES
    • MYOPERICARDITIS
    • THE BOTTOM LINE
    • BACK TO THE CASE SCENARIO
    • DISCLOSURES
    • Acknowledgment
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • What diagnostic tests should be done after discovering clubbing in a patient without cardiopulmonary symptoms?
  • Does my adult patient need a measles vaccine?
  • Do I need to treat supine hypertension in my hospitalized patient?
Show more 1-Minute Consult

Similar Articles

Subjects

  • Cardiology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire